Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01584076 · ClinicalTrials.gov registry record · Phase 1
Treatment of Residual Amblyopia With Donepezil
A Phase 1 study, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT01584076 is a Phase 1 study that has completed, run by Boston Children's Hospital. The registered enrollment target is 18 participants.
The verdict
NCT01584076, a Phase 1 study, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Amblyopia is the leading cause of monocular visual impairment in children and adults. Despite conventional treatment with patching or eye drops, many older children and adults do not achieve normal vision in the amblyopic eye. Donepezil is an acetylcholinesterase inhibitor that increases levels of the neurotransmitter acetylcholine in the brain. Use of acetylcholinesterase inhibitors has been demonstrated by the Hensch lab (Department of Neurology, FM Kirby Neurobiology Center) at Boston Children's Hospital to improve vision and reverse amblyopia in animal models. The purpose of this study is to evaluate the efficacy of oral donepezil as treatment for residual amblyopia (20/50 - 20/400) in patients 8 years of age and older.
Interventions
- OTHER Patching
- DRUG Donepezil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-08 |
| Est. Completion | 2021-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01584076
The ClinicalTrials.gov registry entry for NCT01584076 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Patching is the first listed.
NCT01584076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01584076 about?
NCT01584076 is a clinical study titled "Treatment of Residual Amblyopia With Donepezil". Amblyopia is the leading cause of monocular visual impairment in children and adults. Despite conventional treatment with patching or eye drops, many older children and adults do not achieve normal vision in the amblyopic eye. Donepezil is an acetylcholinesterase inhibitor that increases levels of ...
What is the current status of trial NCT01584076?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-08. Estimated completion is 2021-01.
What interventions are being tested in trial NCT01584076?
The interventions under investigation include: Patching (OTHER), Donepezil (DRUG).
Who is sponsoring clinical trial NCT01584076?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.